A date has been set for the first Taxotere bellwether trial. Court proceedings are now scheduled to begin on September 24, 2018 in the Eastern District of Louisiana.
This bellwether trial will be the first in a small group of lawsuits chosen from the over 1200 Taxotere lawsuits currently filed. The outcomes of these initial bellwether trials will likely shape the process for addressing the remaining cases and often lead to a settlement.
The plaintiffs involved in the litigation have claimed that they were not warned prior to taking Taxotere that it could cause alopecia, a medical condition in which the immune system attacks hair follicles, resulting in hair loss. While hair loss is often a common occurrence with chemotherapy, plaintiffs have alleged that Taxotere is far more likely to cause permanent alopecia compared to other equally effective cancer drugs.
Taxotere was introduced to the U.S. market in 1996 but it wasn’t until late 2015 that a warning was added to the labeling, noting “cases of permanent alopecia have been reported.” This potential side effect had been warned about to doctors and patients in Europe as early as 2005. The Canadian warning label for Taxotere had been updated in 2012.
Studies put the risk of permanent alopecia resulting from taking Taxotere is between 6 and 10 percent. With many equally effective chemotherapy drugs on the market proven not to cause permanent hair loss, many plaintiffs are left wondering why they were never warned about Taxotere, or offered the option of alternative drugs.
At Saunders & Walker, we continue to represent patients harmed by dangerous drugs and defective medical devices. For cancer patients undergoing chemotherapy hair loss is often a trauma. When that hair loss becomes permanent it becomes a difficult reminder that they remain victims of the disease.
If you or a loved has taken Taxotere for cancer treatment, and it resulted in permanent hair loss, please contact us immediately for a free consultation.